Highlights

  • Austco Healthcare (ASX:AHC) reported record FY26 Revenue of A$94.2 million, up 16%.
  • NPAT increased 52% to A$9.0 million, while EBITDA rose 14% to A$14.9 million.
  • Software and maintenance agreement revenue grew 19% to A$11.4 million.
  • Unfilled Contracted Revenue reached A$51.2 million, providing visibility entering FY27.

Austco Healthcare (ASX:AHC) has strengthened its financial and operational profile after delivering record FY26 revenue alongside higher EBITDA, margins and statutory profit. The clinical communications specialist continues to expand through a combination of organic growth, acquisitions and a rising contribution from software and maintenance revenue.

At the time of writing on 28 August 2026, Austco Healthcare was trading at AUD 0.25, up 13.64%, or AUD 0.030, for the session.

The FY26 result released on 27 August 2026 showed continued progress across the company's global healthcare technology platform, while its contracted order book and growing software base provide additional visibility heading into FY27.

Recent Developments

Austco reported FY26 revenue from customers of A$94.2 million, an increase of A$12.8 million, or 16%, from A$81.4 million in FY25.

The result marked another annual revenue record and reflected a combination of organic growth across existing operations and a full-year contribution from G&S, the company's most recent acquisition.

Growth was particularly strong during the first half, when revenue reached A$48.2 million, up 30.7% from the prior corresponding period. Second-half revenue was A$46.0 million, representing growth of 3.4%, with management attributing the softer increase to the timing of larger installation and project-based revenue.

Austco Healthcare (ASX:AHC) also delivered a notable increase in profitability. EBITDA rose 14% to A$14.9 million from A$13.0 million, while statutory net profit before tax increased 44% to A$11.6 million.

NPAT climbed 52% to a record A$9.0 million from A$5.9 million in FY25.

Software Growth

Software and Software Maintenance Agreement revenue continued to expand, rising 19%, or A$1.8 million, to A$11.4 million in FY26.

SMA revenue increased by A$1.1 million, while perpetual software licence revenue contributed an additional A$0.7 million of growth.

Software and maintenance revenue represented 12.0% of total revenue compared with 11.7% in FY25.

The increasing contribution from software is strategically important because it gives Austco a larger base of higher-margin and Recurring Revenue alongside its traditional hardware and installation activities.

Maintenance agreements typically run for periods ranging from one to five years, giving the group greater visibility over part of its future revenue stream.

Margin Improvement

Gross profit increased 19% to A$50.3 million from A$42.4 million in FY25.

Gross Margin improved to 53.4% from 52.0%, reversing some of the margin pressure experienced during the previous two years as Austco integrated acquired businesses.

Management said US tariffs created uncertainty across the Supply chain and also influenced some customer decisions during the year.

However, input costs have begun to decline modestly, and because of Austco's relatively long sales cycle, management expects further benefits from those lower costs to flow through in future periods.

Integration of acquired businesses is also producing operational and supply-chain efficiencies, with further margin support expected during FY27.

Profitability Trends

Operating expenses increased to A$39.9 million in FY26 from A$32.6 million, reflecting in part a full year of costs associated with G&S.

Overheads represented 42.4% of revenue compared with 40.0% in FY25, as the acquisition-related cost base expanded ahead of softer second-half revenue growth.

Despite those additional costs, EBITDA reached A$14.9 million, while the EBITDA margin came in at 15.8%, compared with 16.0% in FY25.

Net profit before tax increased to A$11.6 million from A$8.1 million.

FY25 included a one-off A$2.2 million contingent consideration expense associated mainly with the Amentco earn-out, while FY26 included a A$0.9 million benefit following a favourable revision to the G&S contingent consideration.

The effective tax rate also normalised to approximately 22%, supporting the increase in NPAT to A$9.0 million.

Contracted Revenue

One of the more important forward-looking indicators is Austco's Unfilled Contracted Revenue.

UCR stood at A$51.2 million as at 17 August 2026, up 13% from A$45.2 million at 30 June 2026.

The measure represents confirmed customer orders that have not yet been delivered and therefore have not been recognised as revenue.

Approximately 80% of the group's contracted revenue was denominated in foreign currencies, meaning exchange-rate movements can materially affect the reported Australian-dollar value.

On a constant-currency basis using exchange rates prevailing on 17 August 2026, UCR was approximately 1% higher over the previous 12 months, compared with a 5% decline on an as-reported basis.

Importantly, the increase from A$45.2 million at the end of June to A$51.2 million in August largely reflected genuine new order intake rather than currency movements.

Business Overview

Austco Healthcare is a global provider of healthcare communications and clinical workflow technology.

Founded in 1986 and headquartered in Port Melbourne, the company supports more than 5,000 healthcare facilities across over 60 countries through direct operations and a global reseller network.

Its product portfolio includes the Tacera IP nurse call platform, Medicom, Pulse Mobile, clinical workflow solutions, real-time location services and enterprise reporting and integration products.

The company has also expanded through acquisitions of authorised resellers, allowing it to bring distribution and customer relationships directly into the group.

All acquisitions completed to date were previously established Austco-authorised resellers, providing the company with familiarity with their markets and customer bases before integration.

Research and Development

Austco invested A$4.8 million in Research and Development during FY26, unchanged from the previous year.

Of that amount, A$2.0 million was capitalised as development expenditure relating primarily to the Tacera clinical communications platform.

The profit-and-loss effect of capitalising this expenditure was partly offset by A$1.6 million in R&D amortisation.

Ongoing Investment in Tacera and related workflow technologies remains important as hospitals increasingly seek integrated systems that improve clinical communication, staff productivity and patient response times.

Cash Position

Austco ended FY26 with A$16.3 million in cash, compared with A$14.5 million a year earlier.

Operating activities generated A$12.5 million in cash, reflecting the company's improved underlying profitability.

Management said the Balance Sheet provides scope for further Acquisition activity without requiring Debt or an Equity raising under current conditions.

The company also paid A$6.0 million of contingent acquisition consideration during FY26 and has a further A$2.5 million obligation due in March 2027.

No Dividend was declared, with the Board preferring to retain cash to support organic investment and additional acquisitions.

What Could Matter Next

Austco enters FY27 with several potential growth drivers.

The A$51.2 million Unfilled Contracted Revenue book provides a base of confirmed future work, while software and maintenance revenue continues to grow faster than group revenue.

The company also expects further benefits from acquisition integration and lower input costs to support margins.

Hospital Capital expenditure programs will remain an important variable because the timing of large healthcare projects can cause fluctuations between reporting periods.

Continued acquisition activity could provide another source of growth, particularly given management's stated preference for deploying available cash into organic and inorganic opportunities.

The broader structural backdrop also remains supportive, with ageing populations and healthcare workforce shortages increasing the need for technology that can improve clinical communication and workflow efficiency.

Risks and Watchpoints

Austco remains exposed to the timing of large installation projects, meaning revenue can be uneven between periods.

The company also operates across multiple regions and currencies, creating meaningful foreign-exchange exposure within both revenue and contracted orders.

Acquisitions can deliver scale but also carry integration risk and may increase the group's Fixed Cost base ahead of revenue benefits.

Changes in hospital capital budgets, procurement cycles or healthcare funding could also influence demand.

US tariffs and broader supply-chain conditions remain additional factors, particularly for hardware-related products.

The Bottom Line

Austco Healthcare's FY26 result showed continued progress across revenue, margins and profitability.

Record revenue of A$94.2 million, EBITDA of A$14.9 million and NPAT of A$9.0 million demonstrate the scale the Business has built over recent years, while higher software and maintenance revenue strengthens the recurring component of earnings.

The A$51.2 million contracted revenue book provides further visibility into FY27, while acquisition integration and lower input costs offer potential margin support.

For Austco Healthcare (ASX:AHC), the next phase will depend on converting contracted work into revenue, sustaining software growth and maintaining disciplined execution across its global expansion strategy.